These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9777183)

  • 21. Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?
    Kontaxakis VP; Vaidakis NM; Christodoulou GN; Valergaki HC
    Neuropsychobiology; 1990; 23(1):38-40. PubMed ID: 2280828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome.
    Tsai JH; Yang P; Yen JY; Chen CC; Yang MJ
    Pharmacotherapy; 2005 Aug; 25(8):1156-9. PubMed ID: 16207109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Catatonia, malignant neuroleptic syndrome and myositis ossificans].
    Topka H; Buchkremer G
    Nervenarzt; 1996 May; 67(5):413-7. PubMed ID: 9005354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroleptic malignant syndrome: further lessons from a case report.
    Casamassima F; Lattanzi L; Perlis RH; Litta A; Fui E; Bonuccelli U; Fricchione G; Cassano GB
    Psychosomatics; 2010; 51(4):349-54. PubMed ID: 20587766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lethal catatonia responding to high-dose olanzapine therapy.
    Cassidy EM; O'Brien M; Osman MF; Finucane J; O'Keane V
    J Psychopharmacol; 2001 Dec; 15(4):302-4. PubMed ID: 11769826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are catatonia and neuroleptic malignant syndrome related conditions?].
    Vesperini S; Papetti F; Pringuey D
    Encephale; 2010 Apr; 36(2):105-10. PubMed ID: 20434626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review.
    Chiou YJ; Lee Y; Lin CC; Huang TL
    Medicine (Baltimore); 2015 Oct; 94(43):e1752. PubMed ID: 26512569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].
    Belaizi M; Yahia A; Mehssani J; Bouchikhi Idrissi ML; Bichra MZ
    Encephale; 2013 Jun; 39(3):224-31. PubMed ID: 23095594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine Withdrawal-Induced Malignant Catatonia or Neuroleptic Malignant Syndrome: A Case Report and a Brief Review of the Literature.
    Belteczki Z; Ujvari J; Dome P
    Clin Neuropharmacol; 2021 Jul-Aug 01; 44(4):148-153. PubMed ID: 34132673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catatonia and neuroleptic malignant syndrome: two sides of a coin?
    Vancaester E; Santens P
    Acta Neurol Belg; 2007 Jun; 107(2):47-50. PubMed ID: 17710840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
    Khouri C; Planès S; Logerot S; Villier C; Mallaret M
    Encephale; 2016 Jun; 42(3):277-80. PubMed ID: 26923996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catatonic signs in neuroleptic malignant syndrome.
    Koch M; Chandragiri S; Rizvi S; Petrides G; Francis A
    Compr Psychiatry; 2000; 41(1):73-5. PubMed ID: 10646623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis.
    Osman AA; Khurasani MH
    Br J Psychiatry; 1994 Oct; 165(4):548-50. PubMed ID: 7804674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catatonia and its treatment.
    Rosebush PI; Mazurek MF
    Schizophr Bull; 2010 Mar; 36(2):239-42. PubMed ID: 19969591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosing subtypes of neuroleptic malignant syndrome: an introduction to the Lee-Carroll Scale.
    Carroll BT; Lee JW; Graham KT; Thalassinos A; Thomas C; Kirkhart R
    Ann Clin Psychiatry; 2008; 20(1):47-8. PubMed ID: 18297586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual catatonic state following neuroleptic malignant syndrome.
    Caroff SN; Mann SC; Keck PE; Francis A
    J Clin Psychopharmacol; 2000 Apr; 20(2):257-9. PubMed ID: 10770467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review].
    Asztalos Z; Egervári L; Andrássy G; Faludi G; Frecska E
    Neuropsychopharmacol Hung; 2014 Mar; 16(1):19-28. PubMed ID: 24687015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy.
    Brown CS; Wittkowsky AK; Bryant SG
    Pharmacotherapy; 1986; 6(4):193-5. PubMed ID: 2877444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.
    Woodbury MM; Woodbury MA
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1161-4. PubMed ID: 1429421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical risk factors for neuroleptic malignant syndrome.
    Berardi D; Dell'Atti M; Amore M; De Ronchi D; Ferrari G
    Hum Psychopharmacol; 2002 Mar; 17(2):99-102. PubMed ID: 12404699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.